

PREFACE

- ✦ Infectious Diseases consultation strongly recommended for all cases of nosocomial meningitis

EMPIRIC CHOICES

- ✦ Vancomycin 15-20 mg/kg iv q12h (with loading dose) **PLUS** one of:
 - ceftazidime 2 g iv q8h (or ceftriaxone 2 g iv q12h if basal skull fracture)
- ✦ Adjunctive dexamethasone **NOT** routinely recommended

ROUTE

- ✦ Intravenous (may consider p.o. step-down in cases caused by GNB susceptible to quinolones or TMP-SMX)

DURATION

- ✦ Duration depends on multiple factors: 1) pathogen, 2) presence and removal of CSF shunt device, 3) presence of brain abscess, 4) presence of skull bone involvement (i.e., osteomyelitis), 5) clinical response to therapy
 - **Meningitis**
 - *S. aureus* – 14 days
 - Coagulase-negative staphylococci (CNST) – 7 days
 - Gram-negative bacilli – 21 days
 - **Shunt infection** – Device removal almost always required for clearance of organisms
 - CNST – 7 days minimum, continue 7 days beyond shunt removal
 - *S. aureus* – 14 days
 - GNB – 21 days

ALTERNATIVES FOR ALLERGIES

- ✦ If severe beta-lactam allergy, vancomycin PLUS one of: ceftazidime or anti-pseudomonal quinolone

MOST COMMON ORGANISMS

- ✦ *Staphylococcus* species (including MSSA, MRSA and CNST)
- ✦ *Pseudomonas aeruginosa*
- ✦ Enteric gram-negative organisms (including broad-spectrum beta-lactamase producing organisms)
- ✦ *Propionibacterium acnes*
- ✦ Organisms associated with community-associated acute bacterial meningitis far less common

CURRENT RESISTANCE ISSUES

- ✦ Local rates of ESBL and AMP-C producing organisms important in determining whether a carbapenem is indicated as initial therapy

IMMUNOCOMPROMISED HOST CONSIDERATION

- ✦ Pathogens associated with community-associated bacterial meningitis also a consideration
- ✦ Consider addition of *Listeria* coverage (i.e., ampicillin or TMP-SMX) to empiric therapy

ADDITIONAL DIAGNOSTIC AND THERAPEUTIC COMMENTS

- ✦ Diagnosis based on clinical setting, CNS imaging, and cerebrospinal fluid (CSF) analysis (e.g., culture and cell counts)
- ✦ Organisms often considered to be non-pathogenic can be significant in nosocomial meningitis (e.g., CNST)
- ✦ Intra-ventricular antibiotics of unclear benefit and may be considered in cases with persistently positive CSF cultures or inability to remove CNS device

References:

Van de Beek D, Drake JM, & Tunkel AR. *N Engl J Med.* 2010; 362:146-154

Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, & Whitley RJ. Practice Guidelines for the Management of Bacterial Meningitis. *Clinical Infectious Diseases.* 2004;39:1267 -1284

Disclaimer: This document is intended for internal use at Sinai Health System and University Health Network. Recommendations herein are based on existing literature and clinical practice and are subject to change at any time. Please refer to the [Terms and Conditions](#) for more details.